DexCom, Inc. (DXCM)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
87.66-0.14 (-0.16%)
At close: 4:00 PM EDT
People also watch:
PODDNUVAABMDELGXHTWR
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open88.36
Prev Close87.80
Bid69.50 x 100
Ask94.00 x 100
Day's Range86.81 - 89.02
52wk Range47.92 - 96.38
1y Target EstN/A
Market Cap7.35B
P/E Ratio (ttm)-89.27
Beta0.59
Volume898,211
Avg Vol (3m)845,118
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • DexCom, Inc. – Value Analysis (NASDAQ:DXCM) : September 30, 2016
    Capital Cube15 hours ago

    DexCom, Inc. – Value Analysis (NASDAQ:DXCM) : September 30, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives DexCom, Inc. a score of 31. Our analysis is based on comparing DexCom, Inc. with the following peers – Edwards Lifesciences Corporation, Echo Therapeutics, Inc., West Pharmaceutical Services, Inc., Becton, Dickinson and Company, Tandem Diabetes Care, Inc., Quidel Corporation, MGC Diagnostics Corporation, Medtronic Plc, Johnson & Johnson ... Read more (Read more...)

  • DexCom, Inc. breached its 50 day moving average in a Bearish Manner : DXCM-US : September 29, 2016
    Capital Cube2 days ago

    DexCom, Inc. breached its 50 day moving average in a Bearish Manner : DXCM-US : September 29, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for DexCom, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Reuters2 days ago

    U.S. FDA approves Medtronic's 'artificial pancreas' for diabetes

    Medtronic Plc won U.S. approval on Wednesday for an "artificial pancreas" that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day. The U.S. Food and Drug Administration, in its approval of the device, the MiniMed 670G, hailed it as a breakthrough. The device offers type 1 diabetics "greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin," Dr. Jeffrey Shuren, director of the FDA's medical device division, said in a statement.